Composition in the form of an oil-in-water emulsion and uses thereof

ABSTRACT

Composition for topical application in the form of an oil-in-water emulsion containing an oily phase dispersed in an aqueous phase, and a hydrophilic polymer, the composition further containing (1) at least one elastomeric organopolysiloxane and (2) at least one lipophilic compound chosen from lipophilic amino acid compounds and lipophilic salicylic acid compounds. Uses thereof, including topical application to the skin, lips, hair, etc. Stabilization of certain emulsions using a lipophilic compound.

REFERENCE TO PRIOR APPLICATIONS

This application is a divisional application of U.S. Ser. No. 10/685,505filed Oct. 16, 2003, which claims the benefit of priority to U.S.provisional applications 60/427,931 filed Nov. 21, 2002 and 60/427,928filed Nov. 21, 2002, and to French patent applications 0213520 filedOct. 29, 2002, and 0213521 filed Oct. 29, 2002, all incorporated hereinby reference.

FIELD OF THE INVENTION

The present invention relates to a composition in the form of anoil-in-water emulsion comprising an oily phase dispersed in an aqueousphase, and a hydrophilic polymer. Preferably the composition is suitablefor topical application, and preferably contains (1) at least oneelastomeric organopolysiloxane and (2) at least one lipophilicderivative (compound) preferably chosen from lipophilic salicylic acidderivatives (compounds) and lipophilic amino acid derivatives(compounds). While not bound by any theory whatever, it is believed thatthe lipophilic compound makes it possible to obtain a composition thatis stable even in the presence of high amounts of elastomericorganopolysiloxane.

The composition of the invention has the advantage of being stable andgentle on application. It may especially constitute a cosmeticcomposition.

The invention also relates to the use of the composition according tothe invention, especially to combat the signs of ageing of the skinand/or to improve the radiance of the complexion of the skin.

The invention also relates to the use of the composition according tothe invention, and especially to the use of the salicylic acidcompound(s) and/or of the amino acid compound(s), to stabilize anoil-in-water emulsion containing a hydrophilic polymer and anelastomeric organopolysiloxane.

Additional advantages and other features of the present invention willbe set forth in part in the description that follows and in part willbecome apparent to those having ordinary skill in the art uponexamination of the following or may be learned from the practice of thepresent invention. The advantages of the present invention may berealized and obtained as particularly pointed out in the appendedclaims. As will be realized, the present invention is capable of otherand different embodiments, and its several details are capable ofmodifications in various obvious respects, all without departing fromthe present invention. The description is to be regarded as illustrativein nature, and not as restrictive.

BACKGROUND OF THE INVENTION

For various reasons associated in particular with better comfort duringtheir use (softness, emollience and the like), current cosmeticcompositions are usually in the form of an emulsion of the oil-in-water(O/W) type consisting of an aqueous dispersing continuous phase and anoily dispersed discontinuous phase, or of an emulsion of thewater-in-oil (W/O) type consisting of an oily dispersing continuousphase and an aqueous dispersed discontinuous phase. O/W emulsions arethe ones most sought in the cosmetics field, since they comprise anaqueous phase as external phase, which gives them a fresher, less greasyand lighter feel than W/O emulsions when they are applied to the skin.

The emulsions are generally stabilized with suitable emulsifyingsurfactants, which, by virtue of their amphiphilic structure, becomepositioned at the oil/water interface and thus stabilize the disperseddroplets. However, these emulsifiers have the drawback of beingpenetrating and potentially irritant to the skin, eyes and the scalp,especially in the case of individuals with sensitive skin.

In addition, such emulsions may have insufficient cosmetic andphysicochemical properties (oily feel, instability over time).Increasing the surfactant content generally does not solve the problemsmentioned. The required stability is not always achieved and thecosmetic properties are not improved (waxy, heavy feel, lack offreshness on application). Moreover, as mentioned above, it is also notrecommended to use an excessively high content of surfactant for reasonsof harmfulness.

One solution for overcoming the instability of O/W emulsions (creamingand phase separation) consists in introducing into the emulsionthickeners whose function is to create, in the aqueous phase, a gelledmatrix that serves to set the oily droplets and ensures mechanicalmaintenance of the whole emulsion. Moreover, it has been envisaged toreplace the surfactants with hydrophilic polymers comprising in theirchain a hydrophilic portion and a hydrophobic portion, such ascopolymers of C₁₀-C₃₀-alkyl acrylate and of acrylic or methacrylic acid,for instance the product “Pemulen TR2” sold by the company Goodrich, orwith hydrophilic polymers derived from2-acrylamido-2-methylpropanesulphonic acid (AMPS), as described indocument EP-A-815 844.

However, emulsions stabilized with hydrophilic polymers may have acoarse feel. To improve the softness of these emulsions, the Assigneehas sought to incorporate therein compounds that afford softness, andespecially elastomeric organopoly-siloxanes (also known as siliconeelastomers), such as the products sold by Shin-Etsu under the name KSG.However, the Assignee has found that when these elastomericorganopolysiloxanes are introduced in large amount, and especially in anamount of greater than 1% (of active material); they have a tendency todestabilize the emulsion containing the hydrophilic polymer.

One object of the invention is the provision of oil-in-water (O/W)emulsions that show good cosmetic properties (softness), which arestable, i.e. which do not undergo a phase separation and do not releaseoil, irrespective of the amount of silicone elastomer contained in theemulsion.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The inventors have discovered, unexpectedly, that the use of alipophilic salicylic acid derivative or of a lipophilic amino acidderivative, or both, makes it possible to produce oil-in-water emulsionscontaining both a hydrophilic polymer and a silicone elastomer, whichare stable, this stability persisting even when the content of siliconeelastomer is high. In addition, depending on the polymer used and inparticular when the hydrophilic polymer is an AMPS polymer, emulsionsthat are stable even though they may be free of surfactantconventionally used in this type of emulsion may be prepared.

Thus, the present invention relates to a composition in the form of anoil-in-water emulsion comprising an oily phase dispersed in an aqueousphase, and a hydrophilic polymer, characterized in that it contains (1)at least one elastomeric organopolysiloxane and (2) a lipophilicderivative chosen from lipophilic amino acid derivatives, includingsalts, and lipophilic salicylic acid derivatives of formula (I) below ora salt of such a derivative:

in which:

R₁ represents a hydroxyl radical or an ester of formula:

—O—CO—R₄

in which R₄ is a saturated or unsaturated aliphatic radical containingfrom 1 to 26 carbon atoms and preferably from 1 to 18 carbon atoms, anamine or thiol function optionally substituted with an alkyl radicalcontaining from 1 to 18 carbon atoms and preferably from 1 to 12 carbonatoms,

R₂ and R₃, independently of each other, are in position 3, 4, 5 or 6 onthe benzene ring and represent, independently of each other, a hydrogenatom or a radical:

—(O)_(n)—(CO)_(m)—R₅

in which n and m, independently of each other, are each an integer equalto 0 or 1; on condition that R₂ and R₃ are not simultaneously hydrogenatoms;

R₅ represents a hydrogen, a linear, branched or cyclized saturatedaliphatic radical containing from 1 to 18 carbon atoms, an unsaturatedradical containing from 3 to 18 carbon atoms, bearing one to nineconjugated or non-conjugated double bonds, the radicals optionally beingsubstituted with at least one substituent chosen from halogen atoms(fluorine, chlorine, bromine or iodine), trifluoromethyl radicals,hydroxyl in free form or esterified with an acid containing from 1 to 6carbon atoms, or carboxyl in free form or esterified with a loweralcohol containing from 1 to 6 carbon atoms, or an aromatic radicalcontaining from 6 to 10 carbon atoms.

While not bound by any theory of operation whatever, it is believed thatthe lipophilic derivative used in the composition according to theinvention makes it possible to obtain a stable emulsion. A subject ofthe invention is thus also the use of a lipophilic derivative chosenfrom lipophilic salicylic acid derivatives of formula (I) and lipophilicamino acid derivatives, to stabilize an oil-in-water emulsion containingan elastomeric organopolysiloxane and a hydrophilic polymer.

Since the compositions of the invention have a preferred use in the areaof topical application, it preferably contains a physiologicallyacceptable medium. The expression “physiologically acceptable medium”means a non-toxic medium that may be applied to human skin (includingthe interior of the eyelids), lips, nails or hair.

Lipophilic Salicylic Acid Derivatives

The lipophilic salicylic acid derivative(s) preferably used in thecomposition of the invention are compounds of formula (I) above.

Highly preferred salicylic acid derivative of formula (I) include thosewhere R₁ represents a hydroxyl radical, R₂ represents a hydrogen atom,R₃ is in position 5 of the benzene nucleus and R₅ represents a saturatedaliphatic radical containing from 3 to 15 carbon atoms.

According to one preferred embodiment of the invention, the salicylicacid derivative of formula (I) is chosen from 5-n-octanoylsalicylicacid, 5-n-deca-noylsalicylic acid, 5-n-dodecanoylsalicylic acid,5-n-octylsalicylic acid, 5-n-heptyloxysalicylic acid,4-n-heptyloxysalicylic acid, 5-tert-octylsalicylic acid,3-tert-butyl-5-methylsalicylic acid, 3-tert-butyl-6-methylsalicylicacid, 3,5-diisopropylsalicylic acid, 5-butoxysalicylic acid,5-octyloxysalicylic acid, 5-propanoylsalicylic acid,5-n-hexadecanoylsalicylic acid, 5-n-oleoylsalicylic acid,5-benzoylsalicylic acid, monovalent and divalent salts thereof, andmixtures thereof. It is more particularly 5-n-octanoyl-salicylic acid(INCI name: Capryloyl salicylic Acid).

Lipophilic Amino Acid Derivative

The lipophilic amino acid derivative(s) used in the composition of theinvention is preferably a glycine derivative, more particularly acompound of formula (II) below or a salt of such a compound:

in which R is chosen from alkyl (i.e. saturated) and alkenyl (i.e.unsaturated) radicals containing from 6 to 22 carbon atoms andpreferably from 7 to 18 carbon atoms, and R′ is chosen from hydrogen andalkyl radicals containing from 1 to 30 carbon atoms and preferably from1 to 10 carbon atoms. R′ is preferably hydrogen.

Highly preferred compounds of formula (II) include capryloylglycine,which is a compound of formula (II) in which R is CH₃(CH₂)₆ and R′=H;undecylenoylglycine, which is a compound of formula (II) in which R isCH₂═CH(CH₂)₈ and R′=H; and mixtures thereof.

These compounds may be used in unmodified form or in mixtures containingthem. According to one preferred embodiment of the invention, thecapryloyl-glycine is used in the form of the mixture sold by the companySEPPIC under the name Sepicontrol A5, comprising 25% capryloylglycine,3% cinnamon extract and 7% sarcosine in a mixture of water (45%) andhexylene glycol (20%).

One or more lipophilic salicylic acid and/or amino acid derivatives maybe used. The amount of lipophilic derivative(s) may range, for example,from 0.01% to 20%, preferably from 0.05% to 10% and better still from0.1% to 5% by weight relative to the total weight of the composition.

Elastomeric Organopolysiloxane

The composition of the invention comprises at least one elastomericorganopolysiloxane, which is preferably at least partially crosslinked.The term “elastomeric” means a solid, soft, deformable material withviscoelastic properties especially having the consistency of a sponge ora soft sphere. Its modulus of elasticity is such that this materialwithstands deformation and has limited stretchability andcontractability. This material is capable of regaining its originalshape after stretching. This elastomer is formed from polymer chains ofhigh molecular weight, the mobility of which is limited by a uniformnetwork of crosslinking points.

The elastomeric organopolysiloxanes used in the composition according tothe invention are preferably partially or totally crosslinked. They arepreferably in the form of particles. In a particular embodiment theelastomeric organopolysiloxane particles range from 0.1 to 500 μm,preferably from 3 to 200 μm and better still from 3 to 50 μm in size.These particles may have any shape, for example they may be spherical,flat or amorphous.

When they are included in an oily phase, these elastomericorganopolysiloxanes become transformed, depending on the content of oilyphase used, into a product of spongy appearance when they are used inthe presence of small amounts of oily phase, or into a homogeneous gelin the presence of larger amounts of oily phase. The gelation of theoily phase with these elastomers may be total or partial.

Thus, the elastomers of the invention may be conveyed in the form of ananhydrous gel consisting of an elastomeric organopolysiloxane and of anoily phase. The oily phase used in the manufacture of the anhydrous gelof elastomeric organopolysiloxane may comprise one or more oils that areliquid at room temperature (25° C.) and especially those chosen fromhydrocarbon-based oils and/or silicone oils. Advantageously, the oilyphase is a silicone liquid phase, containing one or more oils chosenfrom polydimethylsiloxanes containing a linear or cyclic chain, whichare liquid at room temperature, optionally comprising an alkyl or arylchain that is pendent or at the end of the chain, the alkyl chaincontaining from 1 to 6 carbon atoms.

The elastomeric organopolysiloxanes used according to the invention maybe chosen from the crosslinked polymers described in patent applicationEP-A-0 295 886 and from those described in U.S. Pat. No. 5,266,321.

They are preferably elastomeric organopoly-siloxanes obtained byaddition and crosslinking reaction, in the presence of a catalyst,preferably a catalyst of the platinum type, of at least:

(a) one organopolysiloxane containing two vinyl groups in α-ω positionon the silicone chain per molecule; and

(b) one organopolysiloxane containing at least two hydrogen atoms linkedto a silicon atom per molecule.

The first organopolysiloxane (i) is chosen from polydimethylsiloxanes;it is preferably an α,ω-dimethylvinylpolydimethylsiloxane.

The organopolysiloxane is preferably in a gel obtained according to thefollowing steps:

(a) mixing of the first and second organopoly-siloxanes (i) and (ii);

(b) adding an oily phase to the mixture from step (a);

(c) polymerizing the first and second organopolysiloxanes (i) and (ii)in the oily phase in the presence of a catalyst, preferably a platinumcatalyst.

The elastomeric organopolysiloxanes used in the composition of theinvention may be, for example, those sold under the names: KSG 6 by thecompany Shin-Etsu; Trefil E-505C or Trefil E-506C by the company DowCorning; Gransil (SR-CYC, SR DMF10, SR-DC556) by the company GrantIndustries, or those sold in the form of ready-made gels: KSG 15, KSG16, KSG 17, KSG 18, KSG 26A or KSG 26B from the company Shin-Etsu;Gransil SR 5CYC gel, Gransil SR DMF 10 gel and Gransil SR DC556 gel fromthe company Grant Industries; 1229-02-167 and 1229-02-168 from thecompany General Electric. A mixture of silicone elastomers, andespecially a mixture of these commercial products, may also be used.

The elastomeric organopolysiloxane used in the composition of theinvention is preferably in the form of an anhydrous gel, and especiallyof an anhydrous gel formed from non-spherical particles of elastomericorganopolysiloxane, such as the KSG products. The elastomericorganopolysiloxane is preferably introduced into the oily phase of theemulsion according to the invention.

The elastomeric organopolysiloxane(s) used according to the inventionare present in an amount of active material that varies depending on thedesired aim. This amount may range, for example, from 0.5% to 20%,preferably from 1% to 15% and better still from 5% to 10% relative tothe total weight of the composition.

Hydrophilic Polymers

Hydrophilic polymers are water-soluble or water-dispersible polymers.The expression “water-soluble or water-dispersible polymer” means apolymer which, when introduced into water to a concentration equal to1%, gives a macroscopically homogeneous solution whose lighttransmittance, at a wavelength equal to 500 nm, through a sample 1 cmthick, is at least 10%.

These polymers are gelling agents, and they may be chosen in particularfrom carboxyvinyl polymers; acrylic or methacrylic copolymers; naturalgums; polysaccharides; acrylamide polymers (homopolymers andcopolymers); and mixtures thereof. These polymers may be in unmodifiedform or in the form of a latex (as dispersions).

Examples of carboxyvinyl polymers that may be mentioned includecrosslinked acrylic acid polymers (INCI name: Carbomer), such as theproducts sold under the names Carbopol 980, 981, 954, 2984 and 5984 bythe company Noveon or the products sold under the names Synthalen M andSynthalen K by the company 3 VSA.

Acrylic or methacrylic copolymers that may especially be mentionedinclude copolymers of C₁₀-C₃₀ alkyl acrylates and of acrylic ormethacrylic acid or of an ester thereof, sold under the names PemulenTR1, Pemulen TR2 and Carbopol 1342 by the company Noveon (INCI name:Acrylates/C10-30 Alkyl Acrylate Crosspolymer).

Examples of natural gums that may be mentioned include xanthan gum,gellan gum and carob gum.

Polysaccharides that may especially be mentioned include cellulosederivatives, for instance hydroxypropylmethylcellulose andcarboxymethyl-cellulose.

Acrylamide polymers that may especially be mentioned includepoly(meth)acrylamido (C₁-C₄)alkyl-sulphonic acids. These polymers arepreferably crosslinked and, in addition, they are preferably partiallyor totally neutralized.

Among these polymers that may especially be mentioned are:

-   polyacrylamidomethanesulphonic acid,-   polyacrylamidoethanesulphonic acid,-   polyacrylamidopropanesulphonic acid,-   poly-2-acrylamido-2-methylpropanesulphonic acid,-   poly-2-methylacrylamido-2-methylpropanesulphonic acid,-   poly-2-acrylamido-n-butanesulphonic acid.

Polymers of this type and especially crosslinked and partially ortotally neutralized poly-2-acrylamido-2-methylpropanesulphonic acids areknown, described and prepared in document DE-A-196 25 810.

The preferred poly (meth) acrylamido (C₁-C₄)-alkylsulphonic acids arecrosslinked and at least 90% neutralized. These polymers may becrosslinked especially with a crosslinking unit containing at least twoolefinic double bonds. The crosslinking units containing at least twoolefinic double bonds may be chosen, for example, from dipropyleneglycol diallyl ether, polyglycol diallyl ethers, triethylene glycoldivinyl ether, hydroquinone diallyl ether, tetraallyl-oxyethane or otherallyl or vinyl ethers of polyfunctional alcohols, tetraethylene glycoldiacrylate, triallylamine, trimethylolpropane diallyl ether,methylenebisacrylamide and divinylbenzene.

The crosslinking units containing at least two olefinic double bonds areeven more particularly chosen from those corresponding to generalformula (III) below:

in which R₁ denotes a hydrogen atom or a C₁-C₄ alkyl radical. Thecrosslinking unit may more particularly be trimethylolpropanetriacrylate (R₁=methyl).

The preferred poly (meth) acrylamido (C₁-C₄)-alkylsulphonic acids areespecially poly-2-acrylamido-2-methylpropanesulphonic acids that arecharacterized in that they comprise, randomly distributed:

a) from 906 to 99.96 by weight of units of formula (IV) below:

in which X⁺ denotes a cation or a mixture of cations, including H⁺,b) from 0.01% to 10% by weight of at least one crosslinking unitcontaining at least two olefinic double bonds,the weight proportions being defined relative to the total weight of thepolymer.

X⁺ represents a cation or a mixture of cations chosen in particular froma proton (H⁺), an alkali metal cation, a cation equivalent to that of analkaline-earth metal, or an ammonium ion.

The crosslinked and neutralizedpoly-2-acryl-amido-2-methylpropanesulphonic acid used preferablycomprises from 98% to 99.5% by weight of units of formula (III) and from0.5% to 2% by weight of crosslinking units, the crosslinking unitpreferably being trimethylolpropane triacrylate.

The crosslinked and partially or totally neutralizedpoly-2-acrylamido-2-methylpropanesulphonic acids are generally knownunder the name “Ammonium Polyacrylamido-2-methylpropanesulphonate” or“Ammonium Polyacryldimethyltauramide” (INCI name).

A material that is particularly preferred according to the invention isthe one sold by the company Clariant under the trade name HostacerinAMPS, which is a crosslinked poly-2-acrylamido-2-methyl-propanesulphonicacid partially neutralized with ammonia.

The crosslinked poly (meth) acrylamide (C₁-C₄)-alkylsulphonic acids maybe obtained according to the known preparation process comprising thefollowing steps:

(a) the 2-(meth) acrylamido (C₁-C₄) alkylsulphonic acid monomer in freeform is dispersed or dissolved in a solution of tert-butanol or in asolution of water and tert-butanol;

(b) the monomer solution or dispersion obtained in (a) is neutralizedwith one or more mineral or organic bases, preferably aqueous ammonia,in an amount producing a degree of neutralization of the sulphonic acidfunctions of the polymer ranging from 0 to 100%;

(c) the crosslinking monomer(s) is(are) added to the solution ordispersion obtained in (b);

(d) a standard free-radical polymerization is performed in the presenceof free-radical initiators at a temperature ranging from 10 to 150° C.,the polymer precipitating in the tert-butanol-based solution ordispersion.

Acrylamide polymers that may also be mentioned include the crosslinkedcopolymer of acrylamide and of 2-acrylamido-2-methylpropanesulphonicacid, in particular the mixture sold under the name Sepigel 305 by thecompany SEPPIC, which is in the form of an emulsion containing about 40%of copolymer (INCI name: polyacrylamide/C13-14 Isoparaffin/laureth-7).

The hydrophilic polymer used in the composition of the invention ispreferably introduced into the aqueous phase of the emulsion accordingto the invention.

According to one preferred embodiment of the invention, the hydrophilicpolymer is a crosslinked and partially or totally neutralizedpoly-2-acrylamido-2-methylpropanesulphonic acid, in particular theammonium salt of such an acid.

The amount of hydrophilic polymer(s) active material preferably rangesfrom 0.1% to 10% by weight, preferentially from 0.2% to 5% by weight andbetter still from 0.5% to 2% by weight relative to the total weight ofthe composition.

Oily Phase

Besides the oils that may be present in the elastomericorganopolysiloxane gel, the oily phase may be of any nature and maycomprise oils, waxes or gums that are solid at room temperature, pastyfatty substances of animal, plant, mineral or synthetic origin, andmixtures thereof.

As oils that may be used in the composition of the invention, mentionmay be made especially of:

hydrocarbon-based oils of animal origin, such as perhydrosqualene;

hydrocarbon-based oils of plant origin, such as liquid fatty acidtriglycerides, for example sunflower oil, maize oil, soybean oil, marrowoil, coriander oil, grapeseed oil, sesame seed oil, hazelnut oil,apricot oil, macadamia oil, castor oil, avocado oil, caprylic/capricacid triglycerides such as those sold by the company Stearineries Duboisor those sold under the names Miglyol 810, 812 and 818 by the companyDynamit Nobel;

oils of formula R¹COOR² in which R¹ represents a higher fatty acidresidue containing from 7 to 19 carbon atoms and R² represents abranched hydrocarbon-based chain containing from 3 to 20 carbon atoms,for instance purcellin oil, isopropyl myristate, and alcohol orpolyalcohol octanoates, decanoates or ricinoleates;

linear or branched hydrocarbons of mineral or synthetic origin, such asvolatile or non-volatile liquid paraffins and derivatives thereof,petroleum jelly, polydecenes, and hydrogenated polyisobutene such asParleam® oil;

synthetic ethers of formula R³OR⁴ in which R³ is a C₃ to C₁₉ alkylradical and R⁴ is a C₃ to C₂₀ alkyl radical;

fatty alcohols, for instance octyldodecanol or oleyl alcohol;

partially hydrocarbon-based fluoro oils and/or fluorosilicone oils, forinstance perfluoropolyesters;

silicone oils such as polymethylsiloxanes containing a linear or cyclicsilicone chain, which are liquid or pasty at room temperature,phenyldimethicones, phenyl-trimethicones, polymethylphenylsiloxanes andalkyl-polydimethylsiloxanes with a C₂ to C₂₀ alkyl chain;

mixtures thereof.

According to one preferred embodiment of the invention, the oily phasecomprises at least one volatile oil. The term “volatile oil” means inparticular an oil capable of evaporating, in less than one hour, oncontact with the skin or the lips, especially one having a non-zerovapour pressure ranging in particular from 10⁻³ to 300 mmHg (at roomtemperature and atmospheric pressure) and preferably greater than 0.3mmHg. Volatile oils that may especially be mentioned include volatilesilicone oils, such as polymethylsiloxanes with a linear or cyclicsilicone chain, and especially cyclomethicone silicone oils, forinstance cyclopentasiloxane, cyclohexasiloxane and cyclotetrasiloxane,and mixtures thereof.

The amount of oily phase in the composition of the invention may rangefrom 1% to 50% by weight, preferably from 5% to 40% and better stillfrom 10% to 30% by weight relative to the total weight of thecomposition.

Aqueous Phase

The amount of aqueous phase in the composition of the invention maypreferably range from 50% to 99% by weight, preferably from 60% to 95%and better still from 70% to 90% by weight, relative to the total weightof the composition.

The aqueous phase comprises at least water. It may also comprise one ormore water-soluble solvents. Examples of water-soluble solvents that maybe mentioned include linear or branched monoalcohols containing from 1to 8 carbon atoms, for instance ethanol, propanol, butanol, isopropanoland isobutanol; polyethylene glycols containing from 6 to 80 ethyleneoxides; polyols, for instance propylene glycol, glycerol, isopreneglycol and butylene glycol.

According to one preferred embodiment of the invention, the emulsion ofthe invention is free of surfactant conventionally used in O/W emulsionsand it consequently has the advantage of not being irritating to theskin, particularly sensitive skin. Surfactants, in particular irritatingsurfactants, thus may be excluded. In addition, this emulsion has theadvantage of allowing the incorporation of heat-sensitive active agents,since it can be manufactured at room temperature.

Adjuvants

The compositions of the invention may contain adjuvants. Examples ofadjuvants that may be mentioned include active agents, preservingagents, antioxidants, complexing agents, pH adjusters (acidic or basic),fragrances, bactericides, odour absorbers, fillers, dyestuffs (pigmentsor dyes) and lipid vesicles. These adjuvants can be used in their usualproportions in the cosmetics field, for example from 0.01% to 30% of thetotal weight of the emulsion, and, depending on their nature, they maybe introduced into the aqueous phase and/or into the oily phase of theemulsion, or alternatively into vesicles. These adjuvants and theconcentrations thereof should be such that they do not modify theproperty desired for the emulsion of the invention.

As active agents that may be used in the composition of the invention,examples that may be mentioned include enzymes (for examplelactoperoxydase, lipase, protease, phospholipase or cellulases);flavonoids; moisturizers such as protein hydrolysates; sodiumhyaluronate; polyols, for instance glycerol, glycols, for instancepolyethylene glycols, and sugar derivatives; antiinflammatories;procyannidol oligomers; vitamins, for instance vitamin A (retinol),vitamin E (tocopherol), vitamin C (ascorbic acid), vitamin B5(panthenol) and vitamin B3 (niacinamide), derivatives of these vitamins(especially esters) and mixtures thereof; urea; caffeine; depigmentingagents such as kojic acid, hydroquinone and caffeic acid; salicylic acidand its derivatives; α-hydroxy acids such as lactic acid and glycolicacid, and derivatives thereof; retinoids such as carotenoids and vitaminA derivatives; sunscreens; hydrocortisone; melatonin; extracts of algae,of fungi, of plants, of yeasts or of bacteria; steroids; antibacterialactive agents, for instance 2,4,4′-trichloro-2′-hydroxydiphenyl ether(or Triclosan), 3,4,4′-trichlorocarbanilide (or Triclocarban); mattingagents, for instance fibres; tensioning agents; ceramides; essentialoils; and mixtures thereof; and any active agent that is suitable forthe final aim of the composition.

Examples of steroids that may be mentioned includedehydroepiandrosterone (or DHEA), and also (1) its biological precursorsand derivatives, in particular the salts and esters of DHEA, such asDHEA sulphate and salicylate, 7-hydroxy DHEA, 7-keto DHEA, esters of7-hydroxy and 7-keto DHEA, especially 3-β-acetoxy-7-oxo DHEA, and (2)its chemical precursors and derivatives, in particular sapogenins suchas diosgenin or hecogenin, and/or derivatives thereof such as hecogeninacetate, and/or natural extracts containing it, and especially Dioscoreaextracts, such as wild yam.

The compositions in accordance with the invention may also comprise atleast one organic photoprotective agent and/or at least one mineralphotoprotective agent that is active in the UVA and/or UVB range(absorbers), which are water-soluble or liposoluble, or insoluble in thecosmetic solvents commonly used.

The organic photoprotective agents are preferably chosen especially fromanthranilates; cinnamic derivatives; dibenzoylmethane derivatives;salicylic derivatives and camphor derivatives; triazine derivatives suchas those described in documents U.S. Pat. No. 4,367,390, EP-A-863 145,EP-A-517 104, EP-A-570 838, EP-A-796 851, EP-A-775 698, EP-A-878 469,EP-A-933 376, EP-A-507 691, EP-A-507 692, EP-A-790 243 and EP-A-944624;benzophenone derivatives; β,β-diphenylacrylate derivatives;benzotriazole derivatives; benzalmalonate derivatives; benzimidazolederivatives; imidazolines; bis-benzazolyl derivatives as described indocuments EP-A-669 323 and U.S. Pat. No. 2,463,264; p-aminobenzoic acid(PABA) derivatives; methylenebis(hydroxyphenylbenzotriazole) derivativesas described in documents U.S. Pat. No. 5,237,071, U.S. Pat. No.5,166,355, GB-A-2 303 549, DE-A-197 26 184 and EP-A-893 119; screeningpolymers and screening silicones such as those described especially indocument WO-A-93/04665; dimers derived from α-alkylstyrene, such asthose described in document DE-A-198 55 649; 4,4-diaryl-butadienes asdescribed in documents EP-A-967 200, DE-A-197 46 654, DE-A-197 55 649,EP-A-1 008 586, EP-A-1 133 980 and EP-A-133 981, and mixtures thereof.

The organic photoprotective agents that are more particularly preferredare chosen from the following compounds:

ethylhexyl salicylate sold under the trade name Neo Heliopan OS byHaarmann & Reimer;

ethylhexyl methoxycinnamate sold especially under the trade name ParsolMCX by Hoffmann LaRoche;

octocrylene (2-ethylhexyl α-cyano-β,β-diphenyl-acrylate) sold especiallyunder the trade name Uvinul N539 by BASF;

phenylbenzimidazolesulphonic acid,

Benzophenone-3 or Oxybenzone, sold under the trade name Uvinul M40 byBASF;

Benzophenone-4 sold under the trade name Uvinul MS40 by BASF;

4-methylbenzylidenecamphor sold under the trade name Eusolex 6300 byMerck;

terephthalylidenedicamphorsulphonic acid manufactured under the nameMexoryl SX by Chimex;

disodium phenyldibenzimidazoletetrasulphonate;

2,4,6-tris(diisobutyl 4′-aminobenzalmalonate)-s-triazine;

anisotriazine sold under the trade name Tinosorb S by Ciba Geigy;

butylmethoxydibenzoylmethane sold especially under the trade name Parsol1789 by Hoffmann LaRoche;

and mixtures thereof.

Examples of mineral photoprotective agents (or physical sunblocks) thatmay be mentioned include coated or uncoated metal oxide pigments andnanopigments, especially titanium oxide, iron oxide, zirconium oxide,zinc oxide or cerium oxide, and mixtures thereof, these oxides possiblybeing in the form of optionally coated microparticles or nanoparticles(nanopigments).

Examples of fillers that may be mentioned include polyamide (Nylon)particles and especially those sold under the name Orgasol by thecompany Atochem; polyethylene powders; microspheres based on acryliccopolymers, such as those made of ethylene glycol dimethacrylate/laurylmethacrylate copolymer, sold by the company Dow Corning under the namePolytrap; polymethyl methacrylate microspheres, sold under the nameMicrosphere M-100 by the company Matsumoto or under the name CovabeadLH85 by the company Wackherr; ethylene-acrylate copolymer powders, forinstance those sold under the name Flobeads by the company SumitomoSeika Chemicals; expanded powders such as hollow microspheres andespecially microspheres formed from a terpolymer of vinylidene chloride,of acrylonitrile and of methacrylate and sold under the name Expancel bythe company Kemanord Plast under the references 551 DE 12 (particle sizeof about 12 μm and density of 40 kg/m³), 551 DE 20 (particle size ofabout 30 μm and a density of 65 kg/m³) and 551 DE 50 (particle size ofabout 40 μm), or the microspheres sold under the name Micropearl F 80 EDby the company Matsumoto; powders of natural organic materials such asstarch powders, especially of corn starch, wheat starch or rice starch,which may or may not be crosslinked, such as the starch powderscrosslinked with octenylsuccinate anhydride, sold under the name Dry-Floby the company National Starch; silicone resin microbeads such as thosesold under the name Tospearl by the company Toshiba Silicone, especiallyTospearl 240; silica; metal oxides such as titanium dioxide or zincoxide; mica; fibres such as Nylon 6 (or polyamide 6) and Nylon 6,6 (orpolyamide 66) fibres, and mixtures thereof. The amount of filler(s) mayrange, for example, from 0.05% to 20% by weight and better still 0.1% to10% by weight relative to the total weight of the composition.

The composition of the invention is preferably used in topicalapplication and it may in particular constitute a cosmetic ordermatological composition. This composition may be more or less fluidand may have the appearance of a white or coloured cream, an ointment, amilk, a lotion, a serum, a paste or a mousse. The composition of theinvention may be applied topically to the human face, including aroundthe eyes, the body and also the scalp.

The composition that is the subject of the invention finds applicationespecially in a wide variety of cosmetic treatments of the skin, thelips and the hair, including the scalp, especially for treating,protecting, caring for, removing makeup from and/or cleansing the skin,the lips and/or the hair, and/or for making up the skin and/or the lips(with incorporation of pigments and/or dyes) and/or for antisunprotection (with incorporation of photo-protective agents). It may beintended in particular for combating the signs of ageing of the skin,for instance an anti-ageing composition for the skin, and especially forimproving the radiance of the complexion of the skin. It may be used inany other application, especially for the skin, that is suitable for thedesired aim depending on the active agents present in the composition.

Thus, one subject of the invention is also the cosmetic use of thecosmetic composition as defined above for treating, protecting, caringfor, removing makeup from and/or cleansing the skin, the lips and/or thehair, and/or for making up the skin and/or the lips.

Another subject of the invention is a cosmetic process for treating theskin, including the scalp, the hair and/or the lips, characterized inthat a cosmetic composition as defined above is applied to the skin, thehair and/or the lips.

Another subject of the invention is the cosmetic use of a cosmeticcomposition as defined above to combat the signs of ageing of the skinand/or to improve the radiance of the complexion of the skin.

The examples that follow will enable the invention to be understood moreclearly, without, however, being limiting in nature. The amountsindicated are weight percentages, unless otherwise mentioned.

Example 1 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company 2% Hoechst)Preserving agents 0.4%   Dye 0.8%   Demineralized water qs 100% Oilyphase: Cyclopentasiloxane 6% KSG 16 (containing 24% active material) 5%(i.e. 1.2% active material) 5-n-octanoylsalicylic acid 0.01%  

Procedure:

The water, the preserving agents and the dyes are heated at 75/80° C.The AMPS is dispersed therein with stirring until a smooth, transparentgel is obtained. The mixture is cooled to 55° C., followed by additionwith stirring of the cyclopentasiloxane and the 5-n-octanoylsalicylicacid. The mixture is cooled to about 40° C. and the KSG-16 is added withstirring, followed by cooling to room temperature.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 1

A composition identical to that of Example 1 but not containing any5-n-octanoylsalicylic acid is prepared. The emulsion obtained is notparticularly smooth, and shows under a microscope large globules of KSG.

Example 2 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company   2% Hoechst)Preserving agents 0.4% Dye 0.8% Demineralized water qs 100% Oily phase:Cyclopentasiloxane   6% KSG 16 (containing 24% active material)  15%(i.e. 3.6% active material 5-n-octanoylsalicylic acid 0.01% 

The procedure is similar to that of Example 1.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are quite well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 2

A composition identical to that of Example 2 but not containing any5-n-octanoylsalicylic acid is prepared. A granular emulsion is obtained,which shows under a microscope large plaques of KSG and KSG deposits onthe edges of the emulsion.

Example 3 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company 2% Hoechst)Preserving agents 0.4%   Dye 0.8%   Demineralized water qs 100% Oilyphase: Cyclopentasiloxane 6% KSG 16 (containing 24% active material) 5%(i.e. 1.2% active material) Undecylenoylglycine 0.1%  

The procedure is similar to that of Example 1.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 3

A composition identical to that of Example 3 but not containing anyundecylenoylglycine is prepared. The emulsion obtained is notparticularly smooth and shows under a microscope large globules of KSG.

Example 4 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company   2% Hoechst)Preserving agents 0.4% Dye 0.8% Demineralized water qs 100% Oily phase:Cyclopentasiloxane   6% KSG 16 (containing 24% active material)  15%(i.e. 3.6% active material) Undecylenoylglycine 0.1%

The procedure is similar to that of Example 1.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are quite well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 4

A composition identical to that of Example 4 but not containing anyundecylenoylglycine is prepared. A granular emulsion is obtained, whichshows under a microscope large plaques of KSG and KSG deposits on theedges of the emulsion.

Example 5 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company 2% Hoechst)Preserving agents 0.4%   Dye 0.8%   Demineralized water qs 100% Oilyphase: Cyclopentasiloxane 6% KSG 16 (containing 24% active material) 5%(i.e. 1.2% active material) Sepicontrol (mixture containing 25% 1%octanoylglycine)

The procedure is similar to that of Example 1.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 5

A composition identical to that of Example 5 but not containing anyoctanoylglycine is prepared. The emulsion obtained is not particularlysmooth and shows under a microscope large globules of KSG.

Example 6 According to the Invention

Aqueous phase: Hostacerin AMPS (sold by the company   2% Hoechst)Preserving agents 0.4% Dye 0.8% Demineralized water qs 100% Oily phase:Cyclopentasiloxane   6% KSG 16 (containing 24% active material)  15%(i.e. 3.6% active material) Sepicontrol (mixture containing 25%   1%octanoylglycine)

The procedure is similar to that of Example 1.

A smooth cream that is very gentle on the skin is obtained. Under amicroscope, the KSG globules are quite well dispersed and the cream isuniform. This cream is capable of improving the radiance of thecomplexion of the skin while at the same time being very gentle.

Comparative Example 6

A composition identical to that of Example 6 but not containing anyoctanoylglycine is prepared. A granular emulsion is obtained, whichshows under a microscope large plaques of KSG and KSG deposits on theedges of the emulsion.

The above written description of the invention provides a manner andprocess of making and using it such that any person skilled in this artis enabled to make and use the same, this enablement being provided inparticular for the subject matter of the appended claims, which make upa part of the original description and including a composition useful,for example, for topical application in the form of an oil-in-wateremulsion comprising an oily phase dispersed in an aqueous phase, and ahydrophilic polymer, where the composition contains (1) at least oneelastomeric organopolysiloxane and (2) at least one lipophilicderivative (compound) chosen from lipophilic amino acid derivatives(compounds) and lipophilic salicylic acid derivatives (compounds) offormula (I) below or a salt of such a compound:

in which:

R₁ represents a hydroxyl radical or an ester of formula:

—O—CO—R₄

in which R₄ is a saturated or unsaturated aliphatic radical containingfrom 1 to 26 carbon atoms, an amine or thiol function optionallysubstituted with an alkyl radical containing from 1 to 18 carbon atoms,

R₂ and R₃, independently of each other, are in position 3, 4, 5 or 6 onthe benzene ring and represent, independently of each other, a hydrogenatom or a radical:

—(O)_(n)—(CO)_(m)—R₅

in which n and m, independently of each other, are each an integer equalto 0 or 1; on condition that R₂ and R₃ are not simultaneously hydrogenatoms;

R₅ represents a hydrogen, a linear, branched or cyclized saturatedaliphatic radical containing from 1 to 18 carbon atoms, an unsaturatedradical containing from 3 to 18 carbon atoms, bearing one to nineconjugated or non-conjugated double bonds, the radicals possibly beingsubstituted with at least one substituent chosen from halogen atoms(fluorine, chlorine, bromine or iodine), trifluoromethyl radicals,hydroxyl in free form or esterified with an acid containing from 1 to 6carbon atoms, or carboxyl in free form or esterified with a loweralcohol containing from 1 to 6 carbon atoms, or an aromatic radicalcontaining from 6 to 10 carbon atoms.

Preferred embodiments of the invention similarly fully described andenabled include the use of a lipophilic derivative chosen fromlipophilic salicylic acid derivatives of formula (I) and lipophilicamino acid derivatives, and salts thereof, to stabilize an oil-in-wateremulsion containing an elastomeric organopolysiloxane and a hydrophilicpolymer. Such stabilization may be accomplished by addition of theidentified materials, where “addition” includes all orders of additionof materials eventually present in the final emulsion. Similarly enabledis the use of a composition according to the invention for treating,protecting, caring for, removing makeup from and/or cleansing the skin,the lips and/or the hair, and/or for making up the skin and/or the lips.

As used herein, the terms “derivative” and “compound” areinterchangeable, and refer to materials of an identifiable chemicalentity. One of ordinary skill in the art is able to identify alipophilic amino acid compound, a salt thereof, a lipophilic salicylicacid compound, and a salt thereof.

All references, patents, applications, tests, standards, documents,publications, brochures, texts, articles, etc. mentioned herein areincorporated herein by reference. Where a numerical limit or range isstated, all values and subranges therewithin are specifically includedas if explicitly written out.

The above description is presented to enable a person skilled in the artto make and use the invention, and is provided in the context of aparticular application and its requirements. Various modifications tothe preferred embodiments will be readily apparent to those skilled inthe art, and the generic principles defined herein may be applied toother embodiments and applications without departing from the spirit andscope of the invention. Thus, this invention is not intended to belimited to the embodiments shown, but is to be accorded the widest scopeconsistent with the principles and features disclosed herein.

1. A composition in the form of an oil-in-water emulsion comprising anoily phase dispersed in an aqueous phase and a hydrophilic polymer, saidcomposition further comprising: (1) at least one elastomericorganopolysiloxane, and (2) at least one lipophilic compound selectedfrom the group consisting of lipophilic salicylic acid compounds offormula (I) below, and salts thereof:

in which: R₁ represents a hydroxyl radical or an ester of formula:—O—CO—R₄ in which R₄ is at least one selected from the group consistingof a saturated or unsaturated aliphatic radical containing from 1 to 26carbon atoms; an amine; and a thiol function optionally substituted withan alkyl radical containing from 1 to 18 carbon atoms, R₂ and R₃,independently of each other, are in position 3, 4, 5 or 6 on the benzenering and represent, independently of each other, a hydrogen atom or aradical:—(O)_(n)—(CO)_(m)—R₅ in which n and m, independently of each other, areeach an integer equal to 0 or 1; provided that R₂ and R₃ are notsimultaneously hydrogen atoms; and R₅ is selected from the groupconsisting of a hydrogen; a linear, branched or cyclized saturatedaliphatic radical containing from 1 to 18 carbon atoms; an unsaturatedradical containing from 3 to 18 carbon atoms, bearing one to nineconjugated or non-conjugated double bonds, the radicals optionally beingsubstituted with at least one substituent selected from the groupconsisting of halogen atoms, trifluoromethyl radicals, hydroxyl in freeform, hydroxyl esterified with an acid containing from 1 to 6 carbonatoms, carboxyl in free form, carboxyl esterified with a lower alcoholcontaining from 1 to 6 carbon atoms, and an aromatic radical containingfrom 6 to 10 carbon atoms.
 2. The composition according to claim 1,comprising at least one salicylic acid compound selected from the groupconsisting of 5-n-octanoylsalicylic acid, 5-n-decanoylsalicylic acid,5-n-dodecanoylsalicylic acid, 5-n-octylsalicylic acid,5-n-heptyloxysalicylic acid, 4-n-heptyloxysalicylic acid,5-tert-octylsalicylic acid, 3-tert-butyl-5-methylsalicylic acid,3-tert-butyl-6-methylsalicylic acid, 3,5-diisopropylsalicylic acid,5-butoxysalicylic acid, 5-octyloxysalicylic acid, 5-propanoylsalicylicacid, 5-n-hexadecanoylsalicylic acid, 5-n-oleoylsalicylic acid,5-benzoylsalicylic acid, monovalent salts thereof, divalent saltsthereof, and mixtures thereof.
 3. The composition according to claim 1,comprising 5-n-octanoylsalicylic acid.
 4. The composition according toclaim 1, wherein the amount of lipophilic compound(s) is 0.01% to 20% byweight relative to the total weight of the composition.
 5. Thecomposition according to claim 1, wherein the elastomericorganopolysiloxane is obtained by addition and crosslinking reaction, inthe presence of a catalyst, of at least: a first organopolysiloxane (i)containing two vinyl groups in α-ω position on the silicone chain permolecule; and a second organopolysiloxane (ii) containing at least onehydrogen atom linked to a silicon atom per molecule.
 6. The compositionaccording to claim 5, wherein the first organopolysiloxane (i) is anα,ω-dimethylvinylpolydimethylsiloxane.
 7. The composition according toclaim 1, wherein the organopolysiloxane is in a gel obtained accordingto the following steps: (a) mixing of first and secondorganopolysiloxanes (i) and (ii); (b) adding an oily phase to themixture from step (a); (c) polymerizing the first and secondorganopolysiloxanes (i) and (ii) in the oily phase in the presence of aplatinum catalyst.
 8. The composition according to claim 1, wherein theamount of elastomeric organopolysiloxane(s) is 0.5% to 20% by weightrelative to the total weight of the composition.
 9. The compositionaccording to claim 1, wherein the hydrophilic polymer is selected fromthe group consisting of carboxyvinyl polymers; acrylic or methacryliccopolymers; natural gums; polysaccharides; acrylamide polymers, andmixtures thereof.
 10. The composition according to claim 1, wherein thehydrophilic polymer is a poly (meth) acrylamido (C₁-C₄) alkylsulphonicacid.
 11. The composition according to claim 10, wherein thepoly(meth)acrylamido(C₁-C₄)alkylsulphonic acid is crosslinked and atleast 90% neutralized.
 12. The composition according to claim 10,wherein the poly(meth)acrylamido(C₁-C₄)alkylsulphonic acid is apolyacrylamidomethylpropanesulphonic acid comprising, randomlydistributed: a) from 90% to 99.9% by weight of units of formula (IV)below:

in which X⁺ denotes a cation or a mixture of cations, including H⁺, b)from 0.01% to 10% by weight of at least one crosslinking unit comprisingat least two olefinic double bonds, the weight proportions of a) and b)being defined relative to the total weight of the polymer.
 13. Thecomposition according to claim 12, wherein thepolyacrylamidomethylpropanesulphonic acid comprises from 98% to 99.5% byweight of units of formula (IV) and from 0.2% to 2% by weight ofcrosslinking units.
 14. The composition according to claim 1, whereinthe amount of hydrophilic polymer is 0.1% to 10% by weight relative tothe total weight of the composition.
 15. The composition according toclaim 1, wherein the amount of oily phase is 1% to 50% by weightrelative to the total weight of the composition.
 16. The compositionaccording to claim 1, wherein the oily phase comprises at least onevolatile oil.
 17. The composition according to claim 1, wherein it isfree of surfactant.
 18. The composition according to claim 1, in theform of a cosmetic or dermatological composition.
 19. A method fortreating, protecting, caring for, removing makeup from and/or cleansingthe skin, the lips and/or the hair, and/or for making up the skin and/orthe lips, comprising applying the composition of claim 1 thereto. 20.The method of claim 19, wherein said method is a method for treating theskin, the hair and/or the lips comprising applying said composition tothe skin, the hair and/or the lips.
 21. The method of claim 20, whereinsaid method is a method for combating signs of ageing of the skin and/orto improve the radiance of the complexion of the skin.
 22. A stablecomposition in the form of an oil-in-water emulsion comprising an oilyphase dispersed in an aqueous phase and a hydrophilic polymer, saidcomposition further comprising: (1) at least one elastomericorganopolysiloxane dispersed in the oily phase, wherein the elastomericorganopolysiloxane is present in an amount ranging from 1 to 20% byweight with respect to the total weight of the composition and isobtained by addition and crosslinking reaction, in the presence of acatalyst, of at least: a first organopolysiloxane (i) containing twovinyl groups in α-ω position on the silicone chain per molecule; and asecond organopolysiloxane (ii) containing at least one hydrogen atomlinked to a silicon atom per molecule, and (2) at least one lipophiliccompound selected from the group consisting of lipophilic salicylic acidcompounds of formula (I) below, and salts thereof:

in which: R₁ represents a hydroxyl radical or an ester of formula:—O—CO—R₄ in which R₄ is at least one selected from the group consistingof a saturated or unsaturated aliphatic radical containing from 1 to 26carbon atoms; an amine; and a thiol function optionally substituted withan alkyl radical containing from 1 to 18 carbon atoms, R₂ and R₃,independently of each other, are in position 3, 4, 5 or 6 on the benzenering and represent, independently of each other, a hydrogen atom or aradical:—(O)_(n)—(CO)_(m)—R₅ in which n and m, independently of each other, areeach an integer equal to 0 or 1; provided that R₂ and R₃ are notsimultaneously hydrogen atoms; and R₅ is selected from the groupconsisting of a hydrogen; a linear, branched or cyclized saturatedaliphatic radical containing from 1 to 18 carbon atoms; an unsaturatedradical containing from 3 to 18 carbon atoms, bearing one to nineconjugated or non-conjugated double bonds, the radicals optionally beingsubstituted with at least one substituent selected from the groupconsisting of halogen atoms, trifluoromethyl radicals, hydroxyl in freeform, hydroxyl esterified with an acid containing from 1 to 6 carbonatoms, carboxyl in free form, carboxyl esterified with a lower alcoholcontaining from 1 to 6 carbon atoms, and an aromatic radical containingfrom 6 to 10 carbon atoms, wherein the lipophlic compound is present inan amount sufficient to stabilize the composition.